Bayer to Acquire BlueRock Therapeutics for its Cell Therapies

Bayer to Acquire BlueRock Therapeutics for its Cell Therapies

Shots:

  • BlueRock to get $240M in cash as upfront and $360M as development milestones. In 2016, Bayer and Versant Ventures formed a joint venture establishing BlueRock Therapeutics, Bayer currently holds the 40.8% stock in BlueRock and will acquire the remaining stocks with its anticipated closure of transaction in Q3’19
  • The focus of the acquisition is to strengthen Bayer’s cell therapy portfolio with the addition of BlueRock’s CELL+GENE platform and cell therapies pipeline currently focusing on neurology, cardiology & immunology with the expected initiation of the clinical program in Parkinson’s disease in H2’19 and will operate as an independent company
  • BlueRock Therapeutics’ CELL+GENE platform includes a broad intellectual property portfolio and technology platforms including iPSC technology, gene engineering and cell differentiation capabilities and harvests primary cells to develop therapies

Click here to­ read full press release/ article | Ref: Bayer | Image: Bloomberg